Roche bladder cancer drug struggles as medics focus on survival
LONDON (Reuters) - Roche's immunotherapy drug Tecentriq has lost market share to Merck& Co's rival Keytruda since a clinical trial showed the Swiss company's medicine failed to improve overall survival in bladder cancer.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Bladder Cancer | Cancer | Cancer & Oncology | Clinical Trials | Health | Immunotherapy | Merck | Switzerland Health